Study on Optimizing CRT Lead Placement for Non-LBBB Patients Using Advanced Imaging Techniques
The RESYNC-PETCT study aims to enhance the efficacy of cardiac resynchronization therapy (CRT) in a patient population that typically sees limited benefits. Successful outcomes could lead to a paradigm shift in heart failure management, influencing clinical practices and treatment guidelines.
Phase III
Cardiology / Heart Failure
Status
Active
Sponsor
heart failure
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
The RESYNC-PETCT study aims to enhance the efficacy of cardiac resynchronization therapy (CRT) in a patient population that typically sees limited benefits. Successful outcomes could lead to a paradigm shift in heart failure management, influencing clinical practices and treatment guidelines.
Why it matters
The RESYNC-PETCT study aims to enhance the efficacy of cardiac resynchronization therapy (CRT) in a patient population that typically sees limited benefits. Successful outcomes could lead to a paradigm shift in heart failure management, influencing clinical practices and treatment guidelines.
What changed
Trial Update
Analysis
The RESYNC-PETCT study aims to improve CRT response in heart failure patients with non-LBBB or narrow LBBB patterns through advanced imaging guidance.
The RESYNC-PETCT study aims to enhance the efficacy of cardiac resynchronization therapy (CRT) in a patient population that typically sees limited benefits. Successful outcomes could lead to a paradigm shift in heart failure management, influencing clinical practices and treatment guidelines.
Monitor trial results for improvements in LVEF and NYHA classifications, as well as any changes in clinical practice guidelines following the study's outcomes.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Source links
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.